Best Peptides for Longevity (2026): Epitalon, FOXO4-DRI, SS-31 & More
Longevity research has moved beyond lifestyle interventions into molecular biology — targeting the specific cellular mechanisms that drive aging. Peptides are at the forefront of this shift, with compounds that reactivate telomerase, selectively destroy senescent cells, stabilize mitochondrial membranes, and activate cellular defense pathways. From Epitalon's telomere protection to FOXO4-DRI's senolytic precision, these peptides represent some of the most targeted anti-aging interventions currently under investigation. This guide covers the biology of aging, the evidence for each compound, and practical considerations for longevity-focused protocols. For a curated anti-aging protocol, see the Anti-Aging Stack, or take the Peptide Finder Quiz to find compounds matched to your goals.
Last updated: 2026-03-03
Top Picks at a Glance
- 1.Epitalon— Telomerase-activating tetrapeptide linked to lifespan extension in animal models
- 2.FOXO4-DRI— Precision senolytic that selectively destroys senescent cells while sparing healthy tissue
- 3.SS-31 (Elamipretide)— Mitochondrial-targeted peptide that reverses age-related bioenergetic decline
- 4.Humanin— Mitochondrial-derived peptide with cytoprotective and metabolic longevity effects
How Peptides Target the Hallmarks of Aging
Modern aging research identifies specific molecular hallmarks that drive the aging process. Longevity peptides are notable because they target these hallmarks directly rather than addressing symptoms:
- Telomere attrition: Epitalon reactivates telomerase to maintain telomere length — directly addressing the "biological clock" of cell division. Critically short telomeres force cells into senescence or death, depleting regenerative cell pools.
- Cellular senescence: FOXO4-DRI selectively eliminates senescent cells that secrete inflammatory SASP factors damaging surrounding tissue. Senescent cell accumulation is increasingly recognized as a causal driver of age-related disease, not just a consequence.
- Mitochondrial dysfunction: SS-31 stabilizes the inner mitochondrial membrane to restore electron transport chain efficiency and reduce ROS production. MOTS-c (see our energy guide) activates AMPK for mitochondrial biogenesis. Both address the energy decline that underlies aging in every organ system.
- Deregulated nutrient sensing: Humanin and MOTS-c both improve insulin sensitivity and metabolic homeostasis — addressing the nutrient sensing dysregulation that contributes to metabolic syndrome, diabetes, and accelerated aging.
- Loss of proteostasis: NAD+ (through sirtuin activation) and humanin (through ER stress protection) support the protein quality control systems that degrade with age, leading to protein aggregation diseases like Alzheimer's and Parkinson's.
- Epigenetic alterations: NAD+-dependent sirtuins (SIRT1, SIRT3, SIRT6) are epigenetic regulators that maintain youthful gene expression patterns. NAD+ replenishment restores sirtuin activity that declines with age.
This hallmark-targeted approach represents a fundamental shift from symptom management to addressing root causes of aging. For broader anti-aging approaches (including skin, hormonal, and cognitive aspects), see our anti-aging guide.
Longevity Peptide Comparison Table
| Peptide | Aging Hallmark Targeted | Mechanism | Typical Protocol | Evidence Level |
|---|---|---|---|---|
| Epitalon | Telomere attrition | Telomerase activation | 5–10 mg/day, 10–20 day courses | Preclinical + clinical observations |
| FOXO4-DRI | Cellular senescence | Selective senolysis (FOXO4-p53 disruption) | 5–10 mg SubQ, intermittent courses | Preclinical (published in Cell) |
| SS-31 | Mitochondrial dysfunction | Cardiolipin stabilization, ETC repair | 10–40 mg/day SubQ | Phase 2/3 clinical trials |
| Humanin | Nutrient sensing, proteostasis | Cytoprotection, STAT3, IGFBP-3 | 1–4 mg/day SubQ | Preclinical + epidemiological |
Note: SS-31 is the most clinically advanced (Phase 2/3). FOXO4-DRI has the highest-impact publication (Cell). Epitalon has the longest research history (30+ years). Use the peptide calculator for reconstitution.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Senolytics: Clearing Zombie Cells for Longevity
Senescent cells — often called "zombie cells" — are cells that have stopped dividing but refuse to die. They accumulate with age and secrete a cocktail of inflammatory factors, proteases, and growth factors (the senescence-associated secretory phenotype, or SASP) that damages surrounding tissue and promotes further senescence in neighboring cells.
Why senescent cells matter for longevity:
- Senescent cells make up only 1–15% of cells in aged tissues but produce outsized inflammatory effects
- SASP factors drive chronic inflammation ("inflammaging"), tissue dysfunction, and age-related disease
- Transplanting senescent cells into young mice accelerated aging and reduced lifespan
- Clearing senescent cells in mice extended healthspan and lifespan by 25–35%
FOXO4-DRI vs. other senolytics:
Small-molecule senolytics (dasatinib + quercetin, fisetin, navitoclax) work through different mechanisms — primarily inhibiting the BCL-2 anti-apoptotic protein family. FOXO4-DRI is unique in targeting the FOXO4-p53 survival interaction specific to senescent cells. This selectivity is important because it reduces the risk of killing healthy cells that also express BCL-2 family proteins.
The senolytic approach is fundamentally different from anti-inflammatory strategies (which suppress SASP effects without removing the source) — it eliminates the source of inflammatory signaling and allows regenerative replacement from stem cell pools. For inflammation-specific approaches, see our inflammation guide.
Longevity vs. Anti-Aging: Understanding the Difference
While related, "longevity" and "anti-aging" represent different objectives with different peptide approaches:
Anti-aging focuses on reversing or slowing visible signs of aging — skin quality, hair health, body composition, energy levels, cognitive function. Peptides like GHK-Cu (collagen and skin rejuvenation), sermorelin (GH optimization), and OS-01 (skin senolytic) target these aspects. See our anti-aging guide for this approach.
Longevity targets the fundamental biology of aging — the molecular mechanisms that determine biological age and maximum lifespan. Peptides like Epitalon (telomerase), FOXO4-DRI (senolytics), SS-31 (mitochondrial function), and humanin (cytoprotection) address these root causes. The goal is not just looking younger but extending healthy years of life (healthspan) and potentially total lifespan.
Where they overlap: Mitochondrial peptides (SS-31, MOTS-c) and NAD+ serve both objectives — improved mitochondrial function manifests as better energy and appearance (anti-aging) while also addressing a fundamental hallmark of biological aging (longevity). GHK-Cu, while primarily an anti-aging peptide, also modulates over 4,000 genes in patterns associated with younger biological age.
A comprehensive protocol might combine longevity-focused peptides (addressing root biology) with anti-aging peptides (addressing quality-of-life symptoms) for both healthspan extension and subjective improvement.
Safety and Practical Considerations
Longevity peptides target fundamental cellular processes, demanding careful consideration of potential risks:
Epitalon: Over 30 years of research by the Khavinson group with favorable safety data. Contrary to the theoretical concern that telomerase activation could promote cancer, animal studies showed reduced tumor incidence in Epitalon-treated groups. This may be because Epitalon also restores melatonin production and immune surveillance. Standard protocol uses intermittent courses (10–20 days) rather than continuous use.
FOXO4-DRI: The selectivity for senescent cells is its primary safety advantage — healthy cells are not affected because they do not depend on FOXO4-p53 for survival. However, rapid clearance of large numbers of senescent cells could theoretically cause temporary inflammatory effects as cell debris is processed. Intermittent dosing (not continuous) allows stem cell pools to replenish cleared senescent cells with functional replacements. Long-term human safety data is not available.
SS-31: The most extensive clinical safety data among longevity peptides, from Phase 2/3 trials. Generally well-tolerated with injection site reactions and mild headache as the most common effects. Its highly targeted mechanism (cardiolipin binding) limits off-target effects.
Humanin: As an endogenous mitochondrial-derived peptide, humanin is expected to have favorable safety. Levels decline naturally with age, suggesting supplementation restores physiological levels rather than creating supraphysiological exposure. Long-term supplementation studies are ongoing.
Critical considerations:
- Individuals with active cancer should not use telomerase activators (Epitalon) or growth-promoting peptides without oncologist clearance
- Senolytic protocols should be intermittent, not continuous — stem cell pools need time to replace cleared cells
- Longevity biomarkers (telomere length, DNA methylation age, inflammatory markers) can help track responses objectively
- Peptides complement but do not replace fundamental longevity practices — caloric optimization, exercise, sleep, stress management
- Source from reputable suppliers with third-party COAs; follow proper reconstitution and storage procedures
Citations
- Khavinson VK, et al. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med. 2003;135(6):590-592. PMID: 14501183
- Baar MP, et al. "Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging." Cell. 2017;169(1):132-147. PMID: 28340339
- Siegel MP, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." Aging Cell. 2013;12(5):763-771. PMID: 23692570
- Kim SJ, et al. "Mitochondrial-derived peptides in aging and age-related diseases." GeroScience. 2021;43(3):1113-1121. PMID: 30236855
- Anisimov VN, et al. "Effect of Epitalon on biomarkers of aging, life span, and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology. 2003;4(4):193-202. PMID: 14501182
Longevity Peptides: Detailed Breakdown
Epitalon
Epitalon (also spelled Epithalon or Epithalone) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the Russian gerontologist Professor Vladimir Khavinson based on decades of research on the pineal gland peptide epithalamin. Epitalon is the most direct peptide-based approach to telomere biology — it activates telomerase, the enzyme that maintains and elongates telomeres (the protective caps on chromosome ends that shorten with each cell division).
Telomere shortening is one of the hallmarks of cellular aging described by Lopez-Otin et al. When telomeres become critically short, cells enter senescence or apoptosis, contributing to tissue dysfunction and aging. Epitalon's ability to reactivate telomerase in human somatic cells potentially extends the replicative lifespan of those cells. In animal studies, Epitalon extended the lifespan of mice and rats, reduced age-related pathology, and maintained youthful gene expression patterns (PMID: 14501183).
Key research findings:
- Activated telomerase in human somatic cells, elongating telomeres in vitro
- Extended mean and maximum lifespan in mouse and rat studies (up to 13.3% increase)
- Restored melatonin production in aged pineal glands — important for circadian rhythm and antioxidant defense
- Reduced incidence of spontaneous tumors in aging animals (contrary to theoretical telomerase/cancer concerns)
- Improved retinal function in age-related retinal degeneration models
- Over 30 years of research by the Khavinson group with multiple published clinical observations
Epitalon is studied at 5–10 mg daily via subcutaneous injection, typically in 10–20 day courses repeated 1–2 times per year. See the complete Epitalon guide.
FOXO4-DRI
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a cell-penetrating peptide designed to selectively induce apoptosis (programmed cell death) in senescent cells — the "zombie cells" that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP) that damage surrounding tissue and drive age-related disease.
The mechanism is elegantly specific: senescent cells survive by maintaining a FOXO4-p53 complex that prevents p53 from triggering apoptosis. FOXO4-DRI disrupts this survival interaction by competing with endogenous FOXO4 for p53 binding. When the FOXO4-p53 complex is disrupted, p53 is released to the mitochondria where it activates the intrinsic apoptotic pathway — but only in senescent cells where this survival mechanism is active. Healthy cells, which do not depend on FOXO4-p53 interaction for survival, are unaffected (PMID: 28340339).
Key research findings:
- Selectively eliminated senescent cells in naturally aged and chemotherapy-treated mice
- Restored physical fitness, fur density, and renal function in aged mice
- Did not harm healthy, non-senescent cells — high selectivity
- Reduced SASP-driven chronic inflammation in treated animals
- Published in Cell (2017) — one of the highest-impact longevity papers in recent years
- D-retro-inverso structure provides protease resistance and cell penetration
FOXO4-DRI is studied at 5–10 mg via subcutaneous injection in intermittent courses (e.g., 3–5 days per month or quarterly). The intermittent dosing reflects that senescent cell clearance triggers regenerative replacement from stem cell pools.
SS-31 (Elamipretide)
SS-31 is one of the most clinically advanced longevity peptides, with Phase 2 and Phase 3 clinical trials investigating its effects on age-related mitochondrial dysfunction. Mitochondrial decline is recognized as a hallmark of aging — as mitochondria age, they produce less ATP, generate more damaging reactive oxygen species (ROS), and lose their ability to maintain cellular energy homeostasis.
SS-31 concentrates over 5,000-fold in the inner mitochondrial membrane by binding cardiolipin — a phospholipid essential for electron transport chain function. By stabilizing cardiolipin-protein interactions, SS-31 restores electron flow through Complexes III and IV, reduces electron leakage that forms ROS, and increases net ATP production. In aged mice, SS-31 treatment reversed skeletal muscle mitochondrial dysfunction to near-youthful levels within hours (PMID: 23692570).
Key research findings:
- Reversed age-related decline in skeletal muscle energetics within hours in aged mice
- Restored mitochondrial ATP production capacity in multiple organ systems
- Reduced mitochondrial ROS production — addressing a primary driver of aging
- Phase 2/3 clinical trials for Barth syndrome and primary mitochondrial myopathy
- Improved cardiac function in heart failure models
- Over 5,000-fold mitochondrial concentration through cardiolipin targeting
SS-31 is studied at 10–40 mg daily via subcutaneous injection. See the complete SS-31 guide and our energy guide for mitochondrial health protocols.
Humanin
Humanin is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome's 16S rRNA gene. Discovered in 2001 during research on Alzheimer's disease, humanin has since been identified as a key mediator of cellular stress response, metabolic regulation, and cytoprotection — making it a significant longevity research target.
Humanin exerts its effects through binding to the FPRL1 receptor, activating the STAT3 signaling pathway, and interacting with IGFBP-3 (insulin-like growth factor binding protein 3) and BAX (a pro-apoptotic protein). These interactions provide broad cytoprotective effects — protecting cells from oxidative stress, endoplasmic reticulum stress, and apoptosis. Circulating humanin levels decline with age in humans, and this decline correlates with increased cardiovascular risk and cognitive decline (PMID: 30236855).
Key research findings:
- Cytoprotective against amyloid-beta toxicity — the primary driver of Alzheimer's disease pathology
- Improved insulin sensitivity and glucose homeostasis in metabolic syndrome models
- Protected against oxidative stress, ER stress, and mitochondrial-mediated apoptosis
- Circulating levels decline with age in humans — correlated with cardiovascular and cognitive risk
- Enhanced autophagy — the cellular recycling process that declines with age
- Reduced atherosclerotic plaque formation in vascular disease models
Humanin analogs (HNG — a potent synthetic variant) are studied at 1–4 mg daily via subcutaneous injection. Research dosing is still being optimized as humanin transitions from basic to translational research.